Stay updated with breaking news from Nasdaq Regn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target boosted by Oppenheimer from $900.00 to $950.00 in a research note released on Friday morning, Marketbeat Ratings reports. Oppenheimer currently has an outperform rating on the biopharmaceutical company’s stock. Several other analysts also recently weighed in on the company. Robert W. Baird cut their target […]
Atlantic Union Bankshares Corp acquired a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 266 shares of the biopharmaceutical company’s stock, valued at approximately $219,000. Other institutional investors have also added […]
NewEdge Wealth LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,596 shares of the biopharmaceutical company’s stock after acquiring an additional 983 shares during […]
NewEdge Wealth LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 20,596 shares of the biopharmaceutical company’s stock after purchasing an additional 983 shares during the period. NewEdge Wealth LLC’s holdings in […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported $10.24 EPS for the quarter, beating the consensus estimate of $8.48 by $1.76, Briefing.com reports. Regeneron Pharmaceuticals had a return on equity of 19.19% and a net margin of 33.93%. The firm had revenue of $3.16 billion for […]